Niihara Y, Zerez CR, Akiyama D, Tanaka KR: Increased red cell glutamine availability in sickle cell anemia: Demonstration of increased active transport, affinity and increased glutamine level in intact red cells. J Lab Clin Med 130:83-90, 1997.
Kim HS, Yospur L, Niihara Y: Chronic lymphocytic leukemia in a patient with sickle cell anemia. West J Med 169:114·116, 1998.
Niihara Y, Zerez CR, Akiyama DS, Tanaka KR: Oral L-glutamine therapy for sickle cell anemia: 1. Subjective clinical improvement and favorable change in red cell NAD redox potential. Am J Hematol 58:117·121, 1998.
Niihara Y, Shalev O, Hebbel RP, Wu H, Tu A, Akiyama DS. Tanaka KR: Desferal (DFO) conjugated with starch decreased NAD redox potential of intact red blood cells (RBC): Evidence for DFO as an extracellular inducer of oxidant stress In RBC. Am J Hematol 65:281-284, 2000.
Lombard M, Xie Y, Niihara Y: Primary care management of sickle cell disease patients. Med Am 2:70-74, 2001.
Curtis M, Leung M, Lam R, Saeed S, Gulati P, Niihara Y: Successful treatment of a patient with pure red cell aplasia with prednisone cyclosporine and antithymocyte globulin. Med Am 2:139-141, 2001.
Takasu J, Uykimpang R, Sunga MA, Amagase H, Niihara Y: Aged Garlic Extract therapy for sickle cell anemia patients. BMC Blood Disorders 2:3, 2002.
Niihara Y, Ge J, Shalev O, Tanaka KR: Desferrioxamine decreases NAD redox potential of intact red blood cells: Evidence for DFO as an inducer of oxidant stress in RBC. BMC Clinical Pharmacology 2:8, 2002.
Niihara Y, Matsui NM, Shen YM, Akiyama DS, Johnson CS, Sunga MA, Magpayo J, Embury SH, Kalra VK, Cho SH, Tanaka KR: L-glutamine therapy reduces endothelial adhesion of sickle red blood cells to human umbilical vein endothelial cells. BMC Blood Disorders 5:4, 2005.